Australian Future Fund

The Future Fund is Australia’s sovereign wealth vehicle, established to manage long-term financial assets on behalf of the Commonwealth, and its private markets activity reaches into pharmaceuticals and digital health primarily through underlying private equity and growth managers. From its Melbourne base it operates as a massive patient-capital allocator rather than a direct venture investor, and named exposure to specific healthcare companies typically appears via GP relationships rather than primary deals. The mandate is intergenerational return, which shapes everything about how the fund engages with risk, duration, and governance. Limited public information about direct healthcare investment partners is available because most activity is intermediated.

Check sizes are 25 million dollars and above at growth stage, with the practical implication that founders rarely raise capital directly from the Future Fund. Geography is global by design, with Australian companies appearing in the portfolio mostly as part of broader manager relationships or large co-investment opportunities. The fund’s healthcare interest covers pharma and therapeutics through specialist managers and digital health through growth funds.

For founders, the realistic engagement model is indirect: a strong relationship with a growth-equity or PE manager that the Future Fund backs as an LP can create a natural path to co-investment at the right scale. Direct outreach to the fund itself is rarely productive for individual companies. Initial conversations, where they happen, should focus on syndicate composition, governance expectations consistent with sovereign capital, and clear alignment between the company’s growth trajectory and the long holding periods this kind of capital requires.